{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:13:28Z","timestamp":1774365208561,"version":"3.50.1"},"reference-count":26,"publisher":"Pleiades Publishing Ltd","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Her. Russ. Acad. Sci."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1134\/s1019331622040104","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:05:31Z","timestamp":1662480331000},"page":"505-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development of Drugs with Direct Antiviral Action Based on Azaheterocyclic Systems"],"prefix":"10.1134","volume":"92","author":[{"given":"V. N.","family":"Charushin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. L.","family":"Rusinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Varaksin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. N.","family":"Chupakhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. P.","family":"Kovtun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Spasov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"7391_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10593-021-02927-1","volume":"57","author":"T. S. Shestakova","year":"2021","unstructured":"T. S. Shestakova, S. L. Deev, I. A. Khalymbadzha, et al., \u201cAntiviral drug Triazavirin, selectively labeled with 2H, 13C, and 15N stable isotopes: Synthesis and properties,\u201d Chem. Heterocycl. Compd. 57 (4), 479\u2212482 (2021).","journal-title":"Chem. Heterocycl. Compd."},{"key":"7391_CR2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5817\/CSF2021-1-18","volume":"70","author":"I. Mal\u00edk","year":"2021","unstructured":"I. Mal\u00edk, J. \u010ci\u017em\u00e1rik, G. Kov\u00e1\u010d, and M. Pech\u00e1\u010dov\u00e1, \u201cTriazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),\u201d \u010ces. Slov. Farm. 70, 18\u201325 (2021).","journal-title":"Slov. Farm."},{"key":"7391_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2174\/1566524020666200521075848","volume":"21","author":"S. Shahab","year":"2021","unstructured":"S. Shahab and M. Sheikhi, \u201cTriazavirin\u2014Potential inhibitor for 2019-nCoV coronavirus M protease: A DFT study,\u201d Curr. Mol. Med. 21 (8), 645\u2013654 (2021).","journal-title":"Curr. Mol. Med."},{"key":"7391_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s10930-020-09945-6","volume":"40","author":"M. A. A. Ibrahim","year":"2021","unstructured":"M. A. A. Ibrahim, A. H. M. Abdelrahman, K. S. Allemailem, et al., \u201cIn silico evaluation of prospective anti-COVID-19 drug candidates as potential SARS-CoV-2 main protease inhibitors,\u201d Protein J. 40 (30), 296\u2013309 (2021).","journal-title":"Protein J."},{"key":"7391_CR5","doi-asserted-by":"crossref","unstructured":"S. Ercan and E. \u00c7\u0131nar, \u201cA molecular docking study of potential inhibitors and repurposed drugs against SARS-CoV-2 main protease enzyme,\u201d J. Indian Chem. Soc. 98 (3), Article no. 100041 (2021).","DOI":"10.1016\/j.jics.2021.100041"},{"key":"7391_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2174\/1386207323999200730205447","volume":"24","author":"S. Chtita","year":"2021","unstructured":"S. Chtita, A. Belhassan, A. Aouidate, et al., \u201cDiscovery of potent SARS-CoV-2 inhibitors from approved antiviral drugs via docking and virtual screening,\u201d Comb. Chem. High Throughput Screen. 24 (3), 441\u2013454 (2021).","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"7391_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s11172-008-0130-8","volume":"57","author":"V. L. Rusinov","year":"2008","unstructured":"V. L. Rusinov, E. N. Ulomskii, O. N. Chupakhin, V.\u00a0N.\u00a0Charushin, \u201cAzolo[5,1-c]-1,2,4-triazines as a new class of antiviral compounds,\u201d Russ. Chem. Bull. 57 (5), 985\u22121014 (2008).","journal-title":"Russ. Chem. Bull."},{"key":"7391_CR8","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3987\/COM-09-S(S)97","volume":"80","author":"O. N. Chupakhin","year":"2010","unstructured":"O. N. Chupakhin, S. L. Deev, T. S. Shestakova, et al., \u201cNon-natural nucleosides based on 1,2,4-triazolo[1,5-a]pyrimidin-7-ones,\u201d Heterocycles 80 (2), 1149\u22121163 (2010).","journal-title":"Heterocycles"},{"key":"7391_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.tet.2013.12.051","volume":"70","author":"I. A. Khalymbadzha","year":"2014","unstructured":"I. A. Khalymbadzha, T. S. Shestakova, J. O. Subbotina, et al., \u201cSynthesis of acyclic nucleoside analogues based on 1,2,4-trizolo[1,5-a]pyrimidin-7-ones by one-step Vorbruggen glycosylation,\u201d Tetrahedron. 70 (6), 1298\u22121305 (2014).","journal-title":"Tetrahedron."},{"key":"7391_CR10","unstructured":"E. G. Deeva, V. L. Rusinov, V. N. Charushin, et al., \u201cAntiviral drug Triazavirin\u00ae: From screening to clinical trials,\u201d Drug Dev. Registr., No. 2, 144\u2013151 (2014)."},{"key":"7391_CR11","first-page":"9","volume":"57","author":"O. I. Kiselev","year":"2012","unstructured":"O. I. Kiselev, E. G. Deeva, T. I. Mel\u2019nikova, et al., \u201cNew antiviral drug Triazavirin: Results of phase II clinical trials,\u201d Probl. Virol. 57 (6), 9\u221212 (2012).","journal-title":"Probl. Virol."},{"key":"7391_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1128\/AAC.01186-09","volume":"54","author":"I. Karpenko","year":"2010","unstructured":"I. Karpenko, S. Deev, O. Kiselev, et al., \u201cAntiviral properties, metabolism, and pharmacokinetics of a\u00a0novel Azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication,\u201d Antimicrob. Agents Chemother. 54 (5), 2017\u22122022 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"7391_CR13","first-page":"18","volume":"52","author":"S. Ya. Loginova","year":"2007","unstructured":"S. Ya. Loginova, S. V. Borisevich, V. A. Maksimov, et al., \u201cStudy of the antiviral activity of triazavirin against the influenza A (H5N1) virus in cell culture,\u201d Antibiot. Chemother. 52 (11\u201312), 18\u221220 (2007).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR14","first-page":"8","volume":"57","author":"S. Ya. Loginova","year":"2012","unstructured":"S. Ya. Loginova, S. V. Borisevich, V. L. Rusinov, et al., \u201cEvaluation of the toxicity of a new domestic anti-influenza chemotherapy drug triazavirin,\u201d Antibiot. Chemother. 57 (11\u201312), 8\u201310 (2012).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.17816\/KMJ2018-215","volume":"99","author":"E. P. Tikhonova","year":"2018","unstructured":"E. P. Tikhonova, T. Yu. Kuz\u2019mina, N. V. Andronova, et al., \u201cStudy of the effectiveness of antiviral drugs (Umifenovir, Triazavirin) against acute respiratory viral infections,\u201d Kazan. Med. Zh. 99 (2), 215\u2212223 (2018).","journal-title":"Kazan. Med. Zh."},{"key":"7391_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.37489\/0235-2990-2021-66-5-6-58-71","volume":"66","author":"A. U. Sabitov","year":"2021","unstructured":"A. U. Sabitov, O. P. Kovtun, N. A. Batskalevich, et al., \u201cMeta-analysis of randomized clinical trials of the efficacy of riamilovir in the etiotropic therapy of influenza,\u201d Antibiot. Chemother. 66 (5\u20136), 58\u221271 (2021).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.37489\/0235-2990-2021-66-5-6-48-57","volume":"66","author":"A. U. Sabitov","year":"2021","unstructured":"A. U. Sabitov, O. P. Kovtun, N. A. Batskalevich, et al., \u201cMeta-analysis of randomized clinical trials of the efficacy of riamilovir in the etiotropic therapy of acute respiratory viral infection,\u201d Antibiot. Chemother. 66 (5\u20136), 48\u221257 (2021).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.37489\/0235-2990-2020-65-7-8-27-30","volume":"65","author":"A. U. Sabitov","year":"2020","unstructured":"A. U. Sabitov, V. V. Belousov, A. S. Edin, et al., \u201cPractical experience with the use of the drug Riamilovir in the treatment of patients with COVID-19 of moderate severity,\u201d Antibiot. Chemother. 65 (7\u20138), 27\u221230 (2020).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.37489\/0235-2990-2020-65-11-12-16-21","volume":"65","author":"K. V. Kas\u2019yanenko","year":"2020","unstructured":"K. V. Kas\u2019yanenko, O. V. Mal\u2019tsev, K. V. Kozlov, et al., \u201cClinical efficacy and safety of riamilovir in the treatment of patients with infection caused by SARS-CoV-2,\u201d Antibiot. Chemother. 65 (11\u201312), 16\u221221 (2020).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR20","first-page":"33","volume":"66","author":"A. U. Sabitov","year":"2021","unstructured":"A. U. Sabitov, P. V. Sorokin, and S. Yu. Dashutina, \u201cEfficacy and safety of Riamilovir in the treatment of patients with COVID-19,\u201d Antibiot. Chemother. 66 (1\u20132), 33\u221237 (2021).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.37489\/0235-2990-2021-66-3-4-49-61","volume":"66","author":"K. A. Zykov","year":"2021","unstructured":"K. A. Zykov, E. A. Sinirsyn, A. V. Rvacheva, et al., \u201cSubstantiation of a new algorithm for outpatient drug therapy of patients with COVID-19 based on the principle of multiple exposures,\u201d Antibiot. Chemother. 66 (3\u20134), 49\u221261 (2021).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.26442\/00403660.2021.03.200719","volume":"93","author":"K. V. Kas\u2019tanenko","year":"2021","unstructured":"K. V. Kas\u2019tanenko, K. V. Kozlov, O. V. Mal\u2019tsev, et al., \u201cEvaluation of the effectiveness of riamilovir in the complex therapy of patients with COVID-19,\u201d Ther. Arch. 93 (3), 290\u2212294 (2021).","journal-title":"Ther. Arch."},{"key":"7391_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.26442\/00403660.2021.04.200751","volume":"93","author":"A. U. Sabitov","year":"2021","unstructured":"A. U. Sabitov, P. V. Sorokin, and S. Yu. Dashutina, \u201cExperience of prophylactic use of the drug Riamilovir in the foci of coronavirus infection (COVID-19),\u201d Ther. Arch. 93 (4), 435\u2013439 (2021).","journal-title":"Ther. Arch."},{"key":"7391_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.37489\/0235-2990-2021-66-7-8-13-19","volume":"66","author":"S. V. Chepur","year":"2021","unstructured":"S. V. Chepur, A. V. Smirnova, A. N. Kirienko, et al., \u201cStudy of the activity of the drug Riamilovir against SARS-CoV-2 infection in Syrian hamsters,\u201d Antibiot. Chemother. 66 (7\u20138), 13\u221219 (2021).","journal-title":"Antibiot. Chemother."},{"key":"7391_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.eng.2020.08.011","volume":"10","author":"X. Wu","year":"2020","unstructured":"X. Wu, K. Yu, Y. Wang, et al., \u201cEfficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial,\u201d Engineering 10, 1185\u22121191 (2020).","journal-title":"Engineering"},{"key":"7391_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10517-022-05489-0","volume":"173","author":"A. A. Spasov","year":"2022","unstructured":"A. A. Spasov, A. F. Kucheryavenko, V. S. Sirotenko, et al., \u201cAntiplatelet activity of riamilovir under conditions of lipopolysaccharide intoxication,\u201d Bull. Exp. Biol. Med. 173, 41\u221245 (2022).","journal-title":"Bull. Exp. Biol. Med."}],"container-title":["Herald of the Russian Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1019331622040104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1019331622040104","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1019331622040104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:39:52Z","timestamp":1774247992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1019331622040104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["7391"],"URL":"https:\/\/doi.org\/10.1134\/s1019331622040104","relation":{},"ISSN":["1019-3316","1555-6492"],"issn-type":[{"value":"1019-3316","type":"print"},{"value":"1555-6492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"29 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}}]}}